Skip to Content

Adakveo Prices, Coupons and Patient Assistance Programs

Adakveo (crizanlizumab) is a member of the miscellaneous uncategorized agents drug class and is commonly used for Anemia - Sickle Cell.

Adakveo Prices

This Adakveo price guide is based on using the discount card which is accepted at most U.S. pharmacies. The cost for Adakveo intravenous solution (10 mg/mL) is around $2,470 for a supply of 10 milliliters, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.

Intravenous Solution

10 mg/mL Adakveo intravenous solution
from $2,470.36 for 10 milliliters
Quantity Per unit Price
10 milliliters $247.04 $2,470.36

Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee. Printable Discount Card

Print Now

The free Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.

Please note: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.

Adakveo Coupons and Rebates

Adakveo offers may be in the form of a printable coupon, rebate, savings card, trial offer, or free samples. Some offers may be printed right from a website, others require registration, completing a questionnaire, or obtaining a sample from the doctor's office.

Adakveo Novartis Universal Co-Pay Card: Eligible commercially insured patients may pay no more than $25 for each of your prescriptions with a maximum savings of $15,000 per year; for additional information contact the program at 877-577-7756.

Applies to:Adakveo
Number of uses:per prescription per calendar year

Patient Assistance Programs for Adakveo

Patient assistance programs (PAPs) are usually sponsored by pharmaceutical companies and provide free or discounted medicines to low income or uninsured and under-insured people who meet specific guidelines. Eligibility requirements vary for each program.

Provider: Novartis Patient Assistance Foundation, Inc. (NPAF)

Elligibility requirements:

  1. Contact program for details.
  2. At or below 600% of FPL
  3. Not specified
  4. The patient must reside in the US, Puerto Rico or the USVI.
  5. For Focalin XR, Clozaril, and Ritalin LA, Clozarila pharmacy card will be issued. All other medication will be shipped directly to the patient, unless otherwise noted. *Additional products may be available. Please contact the program for a complete product listing.

Applicable drugs:

  • Adakveo (crizanlizumab-tmca) Injection; IV

Provider: Patient Access Network Foundation (PAN)

Elligibility requirements:

  1. *See Additional Information section below
  2. Between 400-500% of FPL
  3. FDA Approved Diagnosis - See Program Website for Details
  4. Must reside and receive treatment in US
  5. *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.

Applicable drugs:

  • Adakveo (crizanlizumab-tmca) Injection; IV

Provider: PANO (Novartis Patient Assistance Now Oncology)

Elligibility requirements:

  1. Determined case by case
  2. Income Guidelines published on Program Website
  3. Not specified
  4. The patient must reside in the US, Puerto Rico or the USVI.
  5. Eligibility determined on a case-by-case basis. Uninsured patients, call 1-866-884-5906 Patients with insurance, call 1-800-282-7630 Eligible patients with private insurance may pay $25 per month and Novartis pays the remaining co-pay, up to $15,000 per calendar year, per product.

Applicable drugs:

  • Adakveo (crizanlizumab-tmca) Injection; IV